Skip to content
Screener

Theravance Biopharma TBPH Business Segments — Other General And Administrative Expense

Similar metrics at other companies

ArriVent BioPharma, Inc. logo
AVBPSingle Reportable — Other General And Administrative Expense
$2.31M+7.4%
Capricor Therapeutics logo
CAPRSingle Reportable — Other General And Administrative Expense
$4.12M+199%
Citi Trends logo
CTRNSingle Reportable — Other General And Administrative Expense
$26.41M+9.0%
Scholar Rock logo
SRRKSingle Reportable — Other General And Administrative Expense
$16.6M+11.0%
EVgo, Inc. logo
EVGOSingle Reportable — Other General And Administrative Expense
$12.14M+20.3%
XOM
XOMASingle Reportable — Other General And Administrative Expense
$11.04M+55.7%

Other financials

Income statement

See full
Revenue$20.7M-20.9%
Operating income-$8.3M-204%
Net income-$5.9M-111%
EPS (diluted)-$0.11-110%

Balance sheet

See full
Cash & equivalents$219.8M-22.0%
Total debt$38.6M-17.0%
Total equity$289.7M+28.8%
Total assets$469.8M+10.3%

Cash flow

See full
Operating cash flow$73.3M+70.3%
CapEx$8.0K-95.8%
Free cash flow$59.6M+5,560%

Valuation

See full
Market cap$876.42M+53.8%
Enterprise value$695.22M+108%
P/E16.3×-27.5×
P/S8.4×+1.0×

Profitability

See full
Gross margin60.8%
Operating margin-4%-1.9pp
Net margin51.6%+34.7pp
FCF margin221.9%+206pp

Returns & leverage

See full
Return on equity20.9%+14.7pp
Debt / equity0.1×-0.1×
Current ratio13.5×+6.8×

Where this comes from

Reported directly by Theravance Biopharma in its filing.

Tagged under the XBRL concept us-gaap:OtherGeneralAndAdministrativeExpense.

The source filing: Theravance Biopharma’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 8:00 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-093773
(In thousands)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Employee-related (Research and development) 11,9843,5354,4317,466
External-related (Research and development)1,6005,1903,55210,755
Facilities and other allocated expenses (Research and development)5627781,3651,664
Supporting general and administration functions 15,6198,22113,57915,479
Sales and marketing, and medical affairs 14,9856,65311,89613,958
Share-based compensation4,1384,5437,6149,420
Total recurring operating expenses18,88828,92042,43758,742
Restructuring expenses (including share-based compensation)4,0317,664

Item 1. Financial Statements (unaudited)

FAQ

What is Theravance Biopharma's business segments — other general and administrative expense?
Theravance Biopharma (TBPH) reported business segments — other general and administrative expense of $5.62M in Q2 2026.
How has Theravance Biopharma's business segments — other general and administrative expense changed year-over-year?
Theravance Biopharma's business segments — other general and administrative expense decreased by 31.7% year-over-year, from $8.22M to $5.62M.
What is the long-term trend for Theravance Biopharma's business segments — other general and administrative expense?
Over 2 years (2023 to 2025), Theravance Biopharma's business segments — other general and administrative expense has grown at a -4.0% compound annual growth rate (CAGR), from $31.93M to $29.44M.
What does business segments — other general and administrative expense mean?
This encompasses the broad corporate overhead costs not directly tied to research or marketing, such as legal, finance, and executive management expenses. It is a key metric for evaluating the company's operational discipline and administrative cost control.

Ask your AI about Theravance Biopharma's business segments — other general and administrative expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude